There was good news for Zogenix (Nasdaq: ZGNX) after a meeting with the US Food and Drug Administration (FDA).
The Type A meeting was regarding the resubmission of the New Drug Application (NDA) for Fintepla (fenfluramine) for the treatment of seizures associated with Dravet syndrome.
Zogenix’s initial NDA was met with a Refusal to File (RTF) letter, but the US company now plans to submit a second version in the third quarter of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze